Skip to content

Ombitasvir/Paritaprevir/Ritonavir & Dasabuvir (DSC)

    Discontinued

    DEA Class; Rx

    Common Brand Names; Viekira Pak (DSC)

    • HCV NS5A Inhibitors; 
    • HCV Polymerase Inhibitors; 
    • HCV Protease Inhibitors

    Combination oral product containing 3 antivirals with activity against HCV and a pharmacokinetic enhancer
    For HCV genotype 1a and 1b, including patients with and without compensated cirrhosis
    Contraindicated in patients with moderate to severe hepatic disease (Child-Pugh Class B and C)

    Indicated for the treatment of chronic hepatitis C infection.

    —

    —

    —

    —

    Adults

    500 mg/day PO for dasabuvir; 25 mg/day PO for ombitasvir; 150 mg/day PO for paritaprevir; 100 mg/day PO for ritonavir.

    Geriatric

    500 mg/day PO for dasabuvir; 25 mg/day PO for ombitasvir; 150 mg/day PO for paritaprevir; 100 mg/day PO for ritonavir.

    Adolescents

    Safety and efficacy not established.

    Children

    Safety and efficacy not established.

    Infants

    Safety and efficacy not established.

    Neonates

    Safety and efficacy not established.

    ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) (Discontinued)

    Fixed-dose combination discontinued in 2015 owing to hepatoxicity